Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation
Josiah An(University of Iowa Hospitals and Clinics), Taher Abu Hejleh(University of Iowa), Sarah L. Mott(University of Iowa), Bradley T. Loeffler(University of Iowa), Melissa Yan(Indiana University Health), Adithya Chennamadhavuni(University of Iowa), Mary Pasquinelli(University of Illinois Chicago), Nasser H. Hanna(Ontario Institute for Cancer Research), Lawrence Feldman(University of Illinois Chicago), Muhammad Furqan(University of Iowa), Nanmeng Yu(University of Iowa Hospitals and Clinics), Timothy L. Sita(Northwestern Memorial Hospital), Tim J. Kruser(Northwestern Memorial Hospital)
Cited by 10
Related Papers
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
|Journal of Clinical Oncology|2020|827
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|454
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274